ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004

Reuters

2025/10/24

ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004

ALX Oncology Holdings Inc. announced the presentation of preclinical data and the ongoing Phase 1 clinical trial design for its novel antibody-drug conjugate $(ADC)$ candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Phase 1 trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and preliminary efficacy of ALX2004 in patients with advanced or metastatic solid tumors known to express EGFR. The company reported that preclinical findings have demonstrated potent anti-tumor activity and a favorable toxicity profile. Initial safety data from the ongoing Phase 1 trial are anticipated in the first half of 2026. The results and trial details were presented in poster sessions at the conference, which is taking place from October 22 to 26, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551106-en) on October 23, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577870584"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577870584\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577870584?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577870584","market":"nz","top_or_hot":-1,"title":"ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc. announced the presentation of preclinical data and the ongoing Phase 1 clinical trial design for its novel antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The Phase 1 trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and preliminary efficacy of ALX2004 in patients with advanced or metastatic solid tumors known to express EGFR. The company reported that preclinical findings have demonstrated potent anti-tumor activity and a favorable toxicity profile. Initial safety data from the ongoing Phase 1 trial are anticipated in the first half of 2026. The results and trial details were presented in poster sessions at the conference, which is taking place from October 22 to 26, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551106-en) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-24 00:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc. announced the presentation of preclinical data and the ongoing Phase 1 clinical trial design for its novel antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The Phase 1 trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and preliminary efficacy of ALX2004 in patients with advanced or metastatic solid tumors known to express EGFR. The company reported that preclinical findings have demonstrated potent anti-tumor activity and a favorable toxicity profile. Initial safety data from the ongoing Phase 1 trial are anticipated in the first half of 2026. The results and trial details were presented in poster sessions at the conference, which is taking place from October 22 to 26, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551106-en) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL2DCML4:1","article_id":"2577870584","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577870584","pubTimestamp":1761237015,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ALX Oncology Holdings Inc. announced the presentation of preclinical data and the ongoing Phase 1 clinical trial design for its novel antibody-drug conjugate  candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Phase 1 trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and preliminary efficacy of ALX2004 in patients with advanced or metastatic solid tumors known to express EGFR. The company reported that preclinical findings have demonstrated potent anti-tumor activity and a favorable toxicity profile. Initial safety data from the ongoing Phase 1 trial are anticipated in the first half of 2026. The results and trial details were presented in poster sessions at the conference, which is taking place from October 22 to 26, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","ALXO":"ALX Oncology Holdings","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"ALX Oncology启动新型EGFR靶向ADC ALX2004的1期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXO":0.9,"NDAQ":0.9},"content_text":"ALX Oncology Launches Phase 1 Trial of Novel EGFR-Targeted ADC ALX2004\n    \n\nALX Oncology Holdings Inc. announced the presentation of preclinical data and the ongoing Phase 1 clinical trial design for its novel antibody-drug conjugate $(ADC)$ candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Phase 1 trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and preliminary efficacy of ALX2004 in patients with advanced or metastatic solid tumors known to express EGFR. The company reported that preclinical findings have demonstrated potent anti-tumor activity and a favorable toxicity profile. Initial safety data from the ongoing Phase 1 trial are anticipated in the first half of 2026. The results and trial details were presented in poster sessions at the conference, which is taking place from October 22 to 26, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551106-en) on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}